Simultaneous detection of multiple NT-proBNP clinical samples utilizing an aptamer-based sandwich assay on an integrated microfluidic system

Sinha, Anirban; Gopinathan, Priya; Chung, Yi Da; Shiesh, Shu Chu; Lee, Gwo‐Bin

doi:10.1039/c9lc00115h

Cited by 40 publications

(26 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Related reports indicate that hypoxia-ischemia, microcirculatory disorders, oxidative stress, and stimulation of pro-inflammatory factors lead to increased cardiac secretion of NT-proBNP (10). The only mode of removal of NT-proBNP is glomerular filtration, the level of which is mainly affected by renal function (11), and is not affected by the natriuretic peptide receptor. Some studies also found that elevated serum NT-proBNP in hyponatremia is caused by craniocerebral diseases, such as infection and bleeding (12).…”

Section: Discussionmentioning

confidence: 99%

Clinical value of NT-proBNP measurements in assessing patients in the pediatric intensive care unit

Liu¹,

Luo²,

Chen³

et al. 2021

Transl Pediatr

View full text Add to dashboard Cite

Background: N-terminal brain natriuretic peptide precursor (NT-proBNP) and brain natriuretic peptide (BNP) are mainly produced and secreted in the heart. In 2008, the European Heart Association recommended that serum BNP/NT-proBNP levels should be included in one of the diagnostic criteria of heart failure. Serum NT-proBNP is more stable than BNP, and the detection results are less affected by objective factors, so it is widely used. At present, NT-proBNP has long been beyond the scope of heart failure markers, and has a wide range of clinical value in the evaluation and prediction of some serious diseases. This study prospectively studied the predictive value of serum NT-proBNP in pediatric intensive care unit (PICU).Methods: This was a prospective study involving 375 children in the PICU. The patients were divided into three groups: non-risk, low-risk, and high-risk groups. Serum NT-proBNP levels and the 28-day mortality rate were analyzed. Results:The serum NT-proBNP levels and the mortality of the high-risk group was significantly higher than those of the low-and non-risk groups (P<0.01 in both cases). Receiver operating characteristic curve (ROC curve) analysis showed that the area under the curve was 0.705 (P<0.001, sensitivity =0.643, specificity =0.692). Death multivariate binary logistic regression analysis indicated that NT-proBNP was not an independent factor for 28-day mortality.Conclusions: Serum NT-proBNP was significantly correlated with the severity of illness for critically ill patients in PICU. Although high levels of NT-proBNP indicated greater severity, this was not an independent risk factor affecting the prognosis of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical value of NT-proBNP measurements in assessing patients in the pediatric intensive care unit

Liu¹,

Luo²,

Chen³

et al. 2021

Transl Pediatr

View full text Add to dashboard Cite

show abstract

“…In chronic illnesses, the monitoring of certain biomarkers over time can be reflective of the patient’s recovery or treatment. For many integrated microfluidic devices, tests have been reported to be complete within one hour, with some devices completing the test in only 10 min [ 63 , 64 , 65 , 66 ]. The shorter turnaround time can be combined with shorter detection times to maximize the speed at which results can be obtained from these tests.…”

Section: Integrated Microfluidic-based Platforms (Imps)mentioning

confidence: 99%

Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms

Escobar

Chiu

et al. 2021

Micromachines

View full text Add to dashboard Cite

The rapid detection and quantification of infectious pathogens is an essential component to the control of potentially lethal outbreaks among human populations worldwide. Several of these highly infectious pathogens, such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been cemented in human history as causing epidemics or pandemics due to their lethality and contagiousness. SARS-CoV-2 is an example of these highly infectious pathogens that have recently become one of the leading causes of globally reported deaths, creating one of the worst economic downturns and health crises in the last century. As a result, the necessity for highly accurate and increasingly rapid on-site diagnostic platforms for highly infectious pathogens, such as SARS-CoV-2, has grown dramatically over the last two years. Current conventional non-microfluidic diagnostic techniques have limitations in their effectiveness as on-site devices due to their large turnaround times, operational costs and the need for laboratory equipment. In this review, we first present criteria, both novel and previously determined, as a foundation for the development of effective and viable on-site microfluidic diagnostic platforms for several notable pathogens, including SARS-CoV-2. This list of criteria includes standards that were set out by the WHO, as well as our own “seven pillars” for effective microfluidic integration. We then evaluate the use of microfluidic integration to improve upon currently, and previously, existing platforms for the detection of infectious pathogens. Finally, we discuss a stage-wise means to translate our findings into a fundamental framework towards the development of more effective on-site SARS-CoV-2 microfluidic-integrated platforms that may facilitate future pandemic diagnostic and research endeavors. Through microfluidic integration, many limitations in currently existing infectious pathogen diagnostic platforms can be eliminated or improved upon.

show abstract

“…Monitoring the circulatory levels of a relatively new biomarker, N-terminal prohormone of B-type natriuretic peptide (NT-proBNP), is a meaningful way for the early risk evaluation of HF. Sinha et al [19] developed an ingeniously designed, pneumatically-driven, automatic integrated microfluidic platform equipped with micropumps, micromixers, and microvalves for the simultaneous detection of NT-proBNP (Fig. 5.3).…”

Section: Biomarker Detectionmentioning

confidence: 99%

“…This method may serve as a promising tool for early diagnosis of HF, and the integrated microfluidic chip can be extended for the detection of other Ref. [19] by permission of the Royal Society of Chemistry biomarkers as well when adopting other aptamers. Therefore, it can potentially serve as a promising device providing widespread clinical applications.…”

Section: Biomarker Detectionmentioning

confidence: 99%

Aptamer-Based Medical Devices

Liu

Wang

Zhang

2021

Aptamers for Medical Applications

View full text Add to dashboard Cite

Medical devices have undergone an evolution over thousands of years with the intention to improve the health of people. Aptamers are single-stranded nucleotides that can specifically bind to their targets. They are promising alternatives of antibodies in the field of medical devices owing to the property of specific binding to their targets, as well as the advantages such as easy synthesis and modification, chemical stability, low immunogenicity, and competitive cost, etc. Nevertheless, to our knowledge, there are no aptamer-based medical devices officially approved in the market. Therefore, in this chapter, we first introduced the definition, history, and market of medical devices. Then, some potentially prototypical aptamer-based medical devices related clinical trials, patents, and papers were introduced from two aspects according to their application in "diagnosis" and "therapies," respectively. Finally, we proposed our perspectives and insights for the development of aptamerbased medical devices.

show abstract

Simultaneous detection of multiple NT-proBNP clinical samples utilizing an aptamer-based sandwich assay on an integrated microfluidic system

Abstract: An integrated microfluidic platform was developed for the simultaneous detection of NT-proBNP, a widely studied biomarker for heart failure diagnosis, in up to six clinical samples within 25 min by using a novel aptamer-based sandwich assay.

Cited by 40 publications

References 35 publications

Clinical value of NT-proBNP measurements in assessing patients in the pediatric intensive care unit

Clinical value of NT-proBNP measurements in assessing patients in the pediatric intensive care unit

Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms

Aptamer-Based Medical Devices

Contact Info

Product

Resources

About